新型他汀类药物能够减轻冠状动脉斑块

 
一项研究显示使用他汀类药物降低升高的胆固醇，能够部分逆转冠状动脉斑块的形成。

这项研究在美国、加拿大、欧洲和澳洲的53个社区和III期护理中心进行。总计507例患者接受了基线血管内超声检查(IVUS)，该技术将一个微小超声探头插入冠状动脉中测量斑块。在基线和治疗24小时后测量了动脉粥样硬化的进展。所有患者每日使用40 mg瑞舒伐他汀，该药上市的商品名叫做Crestor。

研究结果显示3种检测方法都发现病变出现了减轻。平均基线低密度脂蛋白(LDL)胆固醇下降了53.2%，平均高密度脂蛋白(HDL)升高了14.7%。根据不同的指标总体判断，动脉斑块减少了6.8-9.1%。这种最大程度的胆固醇降低，曾经在一项大型他汀类药物试验中曾经观察到。这些结果在2006年3月Atlanta (GA, USA)举行的美国心脏病学年度科学会议上进行了报道。
 
Intensive Statin Therapy Reduces Coronary Plaque
 
A new study shows that very intensive cholesterol lowering with a statin drug can partially reverse the buildup of plaque in the coronary arteries.

The study was conducted at 53 community and tertiary care centers in the United States, Canada, Europe, and Australia. A total of 507 patients had baseline intravascular ultrasound (IVUS) examination, a technique in which a tiny ultrasound probe is inserted into the coronary arteries to measure plaque.

Atherosclerosis progression was assessed at baseline and at 24 months of treatment. All patients received 40 mg daily of rosuvastatin, a statin marketed under the brand name Crestor.

Results showed that regression occurred for all three pre-specified IVUS measures of disease burden. The mean baseline low density lipoprotein (LDL) cholesterol dropped by 53.2%, and mean high density lipoprotein (HDL) cholesterol increased by 14.7%. Arterial plaque overall was reduced by 6.8-9.1% for the various measures of disease burden. This is the largest reduction in cholesterol ever observed in a major statin outcome trial. The results were presented at the American College of Cardiology's annual scientific session, held during March 2006 in Atlanta (GA, USA).